期刊文献+

尿黏蛋白7mRNA、尿核基质蛋白和尿脱落细胞学检查对膀胱移行细胞癌的诊断价值比较 被引量:4

原文传递
导出
摘要 尿核基质蛋白(NMP22)测定在临床上已广泛应用于膀胱移行细胞癌的早期诊断检测,但尿黏蛋白7(MUC7)用于膀胱移行细胞癌的早期诊断目前国内外报道较少。笔者选择60例膀胱移行细胞癌和30例非膀胱肿瘤患者同时行尿MUC7mRNA、NMP22和尿脱落细胞学检测,分析比较其诊断膀胱癌中的敏感性、特异性和Youden指数,探讨其诊断膀胱移行细胞癌的临床价值。现报告如下。
作者 黄晨瑛
出处 《中国基层医药》 CAS 2011年第4期545-546,共2页 Chinese Journal of Primary Medicine and Pharmacy
  • 相关文献

参考文献11

二级参考文献23

  • 1N'Dow J,Pearson J P,Bennett M K,et al.Mucin gene expression in human urothelium and in intestinal segments transposed into the urinary tract[J].J Urol,2000,164 (4):1398-1404.
  • 2Retz M,Lehmann J,Roder C,et al.Differential mucin MUC7 gene expression in invasive bladder carcinoma in contrast to uniform MUC1 and MUC2 gene expression in both normal urothelium and bladder carcinoma[J].Cancer Res,1998,58(24):5662-5666.
  • 3Okegawa T,Kinjo M,Horie S,et al.Detection of mucin 7 gene expression in exfoliated cells in urine from patients with bladder tumor[J].Urology,2003,62(1):182-186.
  • 4Retz M,Lehmann J,Amann E,et al.Mucin 7 and cytokeratin 20 as new diagnostic urinary markers for bladder tumor[J].J Urol,2003,169(1):86-89.
  • 5Segal-Eiras R A,Croce M V.Breast cancer associated mucin:a review[J].Allerg Immunopathol,1997,25:176-181.
  • 6Kinjo M,Okegawa T,Horie S,et al.Detection of cir culating MUC7-positive cells by reverse transcriptionpolymerase chain reaction in bladder cancer patients[J].Int J Urol.,2004,11(1):38-43.
  • 7Retz M,Lehmann J,Szysnik C,et al.Detection of occult tumor cells in lymph nodes from bladder cancer patients by MUC7 nested RT-PCR[J].Eur Urol,2004,45(3):314-319.
  • 8Poulter LW.The involvement of dendritic cells in chronic inflammatory disease.Scand J Immunol,1985,21:401.
  • 9Shariat SF,Casella R,Wians FH Jr,et al.Risk stratification for bladder tumor recurrence,stage and grade by urinary nuclear matrix protein 22 and cytology.Eur Urol,2004,45:304-313.
  • 10Dey P.Urinary markers of bladder carcinoma.Clin Chim Acta,2004,340:57-65.

共引文献11

同被引文献24

  • 1张绍谨,刘红耀.尿膀胱癌抗原、核基质蛋白22和透明质酸诊断膀胱癌的临床价值[J].中华临床医师杂志(电子版),2011,5(24):7202-7205. 被引量:15
  • 2何朝宏,肖传国,杜茂信.尿核基质蛋白22在膀胱癌术后复发监测中的应用[J].临床泌尿外科杂志,2005,20(2):107-108. 被引量:3
  • 3沈周俊,胡明明.膀胱癌尿液肿瘤标志物的研究和应用现状[J].临床外科杂志,2009,17(11). 被引量:8
  • 4Ecke TH. Focus on urinary bladder cancer markers: a review[J]. Minerva Urol Nefrol, 2008, 60(4) : 237-246.
  • 5Jemal A, Siegel R, Xu J, et al. Cancer statistics,2010[J]. CA Cancer J Clin, 2010, 60(5) : 277-300.
  • 6Soloway MS, Briggman V, Carpinito GA, et al. Use of a new mark- er, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment[J]. J Urol, 1996, 156(21 Pt) : 363-367.
  • 7Ann JS, Kim HS, Chang SG, et al. The clinical usefulness of nu- clear matrix protein-22 in patients with atypical arine cytology [ J]. Korean J Urol, 2011, 52(9) : 603-605.
  • 8Arora VK, Sarungbam J, Bhatia A, et al. Usefulness of NMP22 as an adjunct to a typical urine cytology and low-grade urothelial carci- noma[J]. Diagn Cytopathol, 2010, 38(11) : 788-790.
  • 9Keesee SK, Briggman JV, Thill G, et al. Utilization of nuclear ma- trix proteins for cancer diagnosis [ J ]. Crit RevEukayotic Gene Expr, 1996, 6(2/3): 189-214.
  • 10Sharmat S, Zippe CD, Pandrangi I, et al. Exclusion criteria en- hance the specificity and positive predictive value of NMP22 and BTAstat[J]. JUrol, 1999, 162(1): 53-57.

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部